A year ago, medical experts and Nobel Laureates interviewed by The New York Times proclaimed "a Golden Age of Medicine" is here.And in the 12 months since, a flurry of new drug and medical discoveries has proven them to be right.From new cancer treatment breakthroughs, to the first-ever FDA-approved genetic editing treatment for illness, new medical advances are helping to cure millions of people from diseases that used to stump scientists.And in the process, the "Golden Age of Medicine" has lit a fire unde ...

Impediments to growth are melting away while new opportunities begin to rise.Eli Lilly (LLY -1.01%) and Novo Nordisk (NVO -1.58%) give new meaning to the word "unstoppable" in the context of pharma stocks. Whereas the total return of Lilly's shares soared by 245% over the last three years, Novo Nordisk's rose by 165%, meaning that both easily beat the broader market's growth of just 25%.There's little indication that either company is about to slow down significantly, even in the face of a couple of headwin ...

Eli Lilly has a lot going for it.Over the last couple of years, the pharmaceutical industry has been taken over by glucagon-like peptide-1 (GLP-1) agonists. Even if you aren't familiar with that terminology, I'd wager that you're well aware of diabetes and obesity medications such as Ozempic, Wegovy, and Mounjaro -- which are all GLP-1 drugs.For now, Denmark-based Novo Nordisk (NVO -1.58%) dominates the GLP-1 market, thanks to its deep roster of treatments including Ozempic, Wegovy, Rybelsus, and Saxenda. H ...

There's no stopping this incredible pharmaceutical stock.Companies worth more than $1 trillion are a rare breed, at least for now. Many more corporations will join this elusive group in the coming years and decades. And the next one to accomplish this feat might be Eli Lilly (LLY -1.01%).The pharmaceutical giant is one of the closest to a $1 trillion market cap among those companies closing in on that milestone. Here is why the drugmaker could beat out its competitors and continue growing long after.Will va ...

These stocks should keep up their winning ways.The recent stock market sell-off appears to have fizzled out and now could be a great time for long-term investors to put some of their cash to work.Three Motley Fool contributors think they've found fantastic growth stocks to buy in August. Here's why they picked Eli Lilly (LLY -1.01%), Novo Nordisk (NVO -1.58%), and Vertex Pharmaceuticals (VRTX 1.14%).A behemoth that could double in sizeDavid Jagielski (Eli Lilly): Growth investors might be tempted to look fo ...

INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Marschall S. Runge, M.D., Ph.D. is retiring from his role as an independent director of Lilly's board of directors effective Aug. 31, 2024.Dr. Runge has served on Lilly's board since 2013, including as a member of the board's Science and Technology Committee and Ethics and Compliance Committee. He is currently the CEO of Michigan Medicine, executive vice president for medical affairs at the University of Michi ...

Eli Lilly (LLY) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this drugmaker, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

With the current market volatility, knowing which biotech stocks to buy on the dip can lead to lucrative returns as the industry is likely to recover faster than the market average. After all, many of the most prominent biomedical developers see their stock price rise or fall based on their drug success.That’s because no matter the market conditions, the critical medicines produced by biotech companies remain in demand by the patient populations that rely on them. For example, the price of insulin, no matte ...

Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.Good afternoon! Novo Nordisk and Eli Lilly have so far dominated the booming market for a class of weight loss and diabetes drugs. But Eli Lilly may be starting to gain an edge over its Danish competitor in the two-horse race to capitalize on the soaring demand for those treatments, also known as GLP-1s. That became clear last week after the pair reported their respective second-quarter earnings. "Lilly is pu ...